Advance Program | ADA 82nd Scientific Sessions - 31

ADVANCE PROGRAM
* The Next Wave of Incretin
Therapeutics-How May They
Impact Care?
High Dose GLP-1 RAs in Treatment of
Type 2 Diabetes-Can They Impact
Therapeutic Inertia?
Carol H. Wysham, MD
Re-thinking Type 2 Diabetes-What is
the Role of GLP-1 Co-agonists?
Julie A. Lovshin, MD, PhD
Availability of High Dose Semaglutide
for Treatment of Obesity-Can this
Impact How We View and Address
Weight?
Sean Wharton, MD, PharmD
GLP-1 RA in the Long Game of CV
Risk Reduction-Scope and Potential
Impact
Lee-Shing Chang, MD
Panel Discussion
* Central Nervous System Control of
Systemic Metabolism
Gut-brain Signaling in the Hypothalamic
Detection of Macronutrients by Multiple
Pathways
J. Nicholas Betley, PhD
Tanacytes in the Hypothalamic Control
of Energy Balance
Vincent Prevot, PhD
Repeated Hypoglycemia Remodels
Neural Inputs and Disrupts
Mitochondrial Function to Blunt
Glucose-Inhibited GHRH Neuron
Responsiveness
Sarah Stanley, MB, BCh, PhD
Role of the VMH in Control of Glucose
Disposal
David Olson, MD, PhD
* Oral Presentations
4:30 p.m.-6:30 p.m.
* Breakthrough! Effective Treatments
for Diabetic Kidney Disease
New Data on the Effects and Clinical
Application of SGLT2 Inhibitors
Janani Rangaswami, MD, FACP
Mineralocorticoid Receptor Antagonists
in High FIDELITY
George Bakris, MD
Combining Drugs to Treat Diabetic
Kidney Disease
Daniël van Raalte, MD, PhD
Consensus-New Joint Statement
from the ADA and KDIGO on
Management of Diabetes and CKD
Peter Rossing, MD, DMSc
* Diabetes with Cardiomyopathy-
Does Anybody Have a Map?
Clinical and Research Importance
of Understanding Diabetes with
Cardiomyopathy
Ileana Piña, MD, MPH
Mechanisms Underlying the
Development of Diabetic
Cardiomyopathy
Lu Cai, MD, PhD
Diagnosing Diabetes with
Cardiomyopathy-Dilemmas and
Recommendations
Ambarish Pandey, MD, MSCS
Clinical Management of Diabetes
with Cardiomyopathy-Current
Management, Future Directions
Pam R. Taub, MD, FACC
Diabetes with Cardiomyopathy-A
Diabetes Perspective
Harold Bays, MD
* Joint ADA/EASD-Management of
Hyperglycemia in Type 2 Diabetes
Introduction and Methods
The Rationale and Importance of
Antihyperglycemic Treatment
Peter Rossing, MD, DMSc
Personalized Approach Based
on Patient Characteristics and
Comorbidities
Jennifer B. Green, MD
Therapeutic Options-Lifestyle
Management and Pharmacologic
Treatment
Vanita R. Aroda, MD
Strategies for Implementing
Antihyperglycemic Treatment Plan
Nisa M. Maruthur, MD, MHS
Key Knowledge Gaps, Question and
Discussion Period
John B. Buse, MD, PhD
* Emerging Data on Therapies to Treat
the Underlying Autoimmunity in Type
1 Diabetes
Antigen Specific Immunotherapy for
Type 1 Diabetes
Matthias G. von Herrath, MD
Biomarkers of Treatment Response to
Immune Therapies
S. Alice Long, PhD
Immune Privileged Stem Cell-Derived
Beta Cells to Treat Diabetes
Audrey Parent, PhD
New Directions for Preventing Type 1
Diabetes
Kevan C. Herold, MD
* Insulin Resistance and Heart Failure
Syndromes Including HFpEF
Nicotinamide Metabolism and Heart
Failure
Rong Tian, MD, PhD
Oxidative Metabolism and Signaling in
Cardiometabolic HFpEF
Gabriele Schiattarella, MD, PhD
SGLT2 Inhibition in HFpEF
The Complex Tapestry of Nitric Oxide
Signaling in the Failing Heart
* Definition and Interpretation of
Remission in Type 2 Diabetes
Optimal Terminology-Can Type 2
Diabetes Remission Be Diagnosed
while Glucose-Lowering Drugs Are
Being Used?
Michael A. Nauck, MD
Glycemic Criteria for Diagnosing
Remission of Type 2 Diabetes and
Temporal Aspect of Diagnosing Type 2
Diabetes Remission
Roy Taylor, MD
Physiologic Considerations Regarding
Remission Following Intervention
with Pharmacotherapy, Lifestyle,
or Metabolic Surgery and Further
Questions and Unmet Needs
Philip Schauer, MD
* Oral Presentations
* Edwin Bierman Award Lecture
Gary Lewis, MBBCH
HYBRID | NEW ORLEANS | JUNE 3-7, 2022 | #ADA2022
Speakers and presentation titles are subject to change.
31

Advance Program | ADA 82nd Scientific Sessions

Table of Contents for the Digital Edition of Advance Program | ADA 82nd Scientific Sessions

Advance Program | ADA 82nd Scientific Sessions - 1
Advance Program | ADA 82nd Scientific Sessions - 2
Advance Program | ADA 82nd Scientific Sessions - 3
Advance Program | ADA 82nd Scientific Sessions - 4
Advance Program | ADA 82nd Scientific Sessions - 5
Advance Program | ADA 82nd Scientific Sessions - 6
Advance Program | ADA 82nd Scientific Sessions - 7
Advance Program | ADA 82nd Scientific Sessions - 8
Advance Program | ADA 82nd Scientific Sessions - 9
Advance Program | ADA 82nd Scientific Sessions - 10
Advance Program | ADA 82nd Scientific Sessions - 11
Advance Program | ADA 82nd Scientific Sessions - 12
Advance Program | ADA 82nd Scientific Sessions - 13
Advance Program | ADA 82nd Scientific Sessions - 14
Advance Program | ADA 82nd Scientific Sessions - 15
Advance Program | ADA 82nd Scientific Sessions - 16
Advance Program | ADA 82nd Scientific Sessions - 17
Advance Program | ADA 82nd Scientific Sessions - 18
Advance Program | ADA 82nd Scientific Sessions - 19
Advance Program | ADA 82nd Scientific Sessions - 20
Advance Program | ADA 82nd Scientific Sessions - 21
Advance Program | ADA 82nd Scientific Sessions - 22
Advance Program | ADA 82nd Scientific Sessions - 23
Advance Program | ADA 82nd Scientific Sessions - 24
Advance Program | ADA 82nd Scientific Sessions - 25
Advance Program | ADA 82nd Scientific Sessions - 26
Advance Program | ADA 82nd Scientific Sessions - 27
Advance Program | ADA 82nd Scientific Sessions - 28
Advance Program | ADA 82nd Scientific Sessions - 29
Advance Program | ADA 82nd Scientific Sessions - 30
Advance Program | ADA 82nd Scientific Sessions - 31
Advance Program | ADA 82nd Scientific Sessions - 32
https://www.nxtbookmedia.com